Oryzon Genomics SA
F:ORN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
F:ORN
|
ES |
|
Partners Group Holding AG
OTC:PGPHF
|
CH |
Intrinsic Value
The intrinsic value of 
Oryzon Genomics SA (ORN) under the Base Case is 0.15 EUR per share.
Compared with the current market price of 2.538 EUR, the stock appears
Overvalued by 94% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Oryzon Genomics Does
Oryzon Genomics is a drug development company focused on medicines that change how genes are switched on and off. Its main work is discovering and testing epigenetic drugs, especially compounds that block LSD1, an enzyme involved in cancer and some brain disorders. The company does not sell everyday consumer products; it builds drug candidates that may eventually be licensed or sold as prescription medicines if they win approval.
- Headquarters
- Spain ES
- Employees
- 46
- IPO date
- Dec 10, 2015
Earnings Waterfall
Oryzon Genomics SA
The intrinsic value for Oryzon Genomics SA (ORN) under the Base Case is 0.15 EUR.
Compared with the current market price of 2.538 EUR, the stock appears Overvalued by 94% .